Premium
Probiotics for the Prevention of Beta Cell Autoimmunity in Children at Genetic Risk of Type 1 Diabetes—the PRODIA Study
Author(s) -
LJUNGBERG MARTIN,
KORPELA RIITA,
ILONEN JORMA,
LUDVIGSSON JOHNNY,
VAARALA OUTI
Publication year - 2006
Publication title -
annals of the new york academy of sciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.712
H-Index - 248
eISSN - 1749-6632
pISSN - 0077-8923
DOI - 10.1196/annals.1375.055
Subject(s) - type 1 diabetes , autoantibody , medicine , autoimmunity , diabetes mellitus , beta (programming language) , immunology , beta cell , pediatrics , endocrinology , antibody , islet , computer science , programming language
The final aim of the PRODIA study is to determine whether the use of probiotics during the first 6 months of life decreases the appearance of type 1 diabetes mellitus (T1DM)‐associated autoantibodies in children with genetic risk for T1DM. A pilot study including 200 subjects was planned to show whether the use of probiotics during the first 6 months of life is safe and feasible. The prevalence of autoantibodies among the study subjects at 6, 12, and 24 months of age was at levels close to the expected and the clinical follow‐up did not either indicate problems in the feasibility of the study.